Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00170677
Status:
COMPLETED
Last Update Posted:
2014-05-14
First Post:
2005-09-13
Brief Title:
Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer
Sponsor:
North Eastern German Society of Gynaecological Oncology
Organization:
North Eastern German Society of Gynaecological Oncology
Study Overview
Official Title:
Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer
Status:
COMPLETED
Status Verified Date:
2010-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Comparison of topotecan weekly vs topotecan day 1-5 The compatibility and activity are to be examined
Detailed Description:
Topotecan belongs to the most effective medicaments in the therapy of relapsed platin-resistant ovarian cancer Due to the low rate of hematological toxicities of grade 3 or 4 weekly application may be an improvement of therapy None randomised study exists comparing a weekly topotecan application with an application on day 1-5 This study will compare the two applications in regard to rate of complete or partial remissions rate of toxicity quality of life progression free survival overall survival
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None